Abstract
Purpose
To describe the clinical and genetic findings of patients in the second Japanese family with Malattia Leventinese/Doyne honeycomb retinal dystrophy (ML/DHRD).
Methods
Two patients (a 41-year-old male proband and his third son) underwent comprehensive ophthalmic examinations, including full-field and multifocal electroretinography (ERG). Sanger sequencing was performed to detect an EFEMP1 gene variant (p.Arg345Trp), which was identified as the only causative pathogenic variant.
Results
Genetic analysis revealed that both patients carried the heterozygous variant, but the other unaffected family members did not. Although the proband exhibited innumerable radially distributed drusen in both the posterior poles and good visual acuity at initial presentation, bilateral choroidal neovascularization (CNV) developed during the 15-year follow-up. The proband received 15 intravitreal anti-vascular endothelial growth factor (VEGF) injections in the left eye (LE) and two injections in the right eye (RE). At 56 years of age, his decimal best-corrected visual acuity was 0.1 and 1.2 in the LE and RE, respectively. Full-field ERG showed that while the rod and combined responses were within normal amplitudes, the cone and 30-Hz flicker responses had slightly decreased amplitudes. Multifocal ERG revealed attenuated central responses in the LE and decreased temporal responses in the RE. In the 20-year-old son, multifocal ERG showed normal responses in both eyes.
Conclusion
This is the first report of ML/DHRD in a patient who developed bilateral CNV and received anti-VEGF treatment in both eyes. Although multifocal ERG exhibited worsening of macular function, the generalized photoreceptor function was preserved until middle age.
Similar content being viewed by others
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
References
Vogt A (1925) Die ophthalmoscopie im rotfreien Licht. In: Graefe A, Saemisch T (eds) Handbuch der gesammten augenheilkunde: untersuchungsmethoden, 3rd edn. Leipez, Verlag von Wilhelm Engelman, Berlin, pp 1–118
Doyne RW (1899) A peculiar condition of choroiditis occurring in several members of the same family. Trans Ophthalmol Soc UK 19:71
Haimovici R, Wroblewski J, Piguet B, Fitzke FW, Holder GE, Arden GB, Bird AC (2002) Symptomatic abnormalities of dark adaptation in patients with EFEMP1 retinal dystrophy (Malattia Leventinese/Doyne honeycomb retinal dystrophy). Eye (Lond) 16:7–15. https://doi.org/10.1038/sj.eye.6700018
Pearce WG (1968) Doyne’s honeycomb retinal degeneration. Clinical and genetic features. Br J Ophthalmol 52:73–78. https://doi.org/10.1136/bjo.52.2.73
Lenassi E, Troeger E, Wilke R, Tufail A, Hawlina M, Jeffery G, Webster AR (2013) Laser clearance of drusen deposit in patients with autosomal dominant drusen (p.Arg345Trp in EFEMP1). Am J Ophthalmol 155:190–198. https://doi.org/10.1016/j.ajo.2012.07.003
Dantas MA, Slakter JS, Negrao S, Fonseca RA, Kaga T, Yannuzzi LA (2002) Photodynamic therapy with verteporfin in mallatia leventinese. Ophthalmology 109:296–301. https://doi.org/10.1016/s0161-6420(01)00927-7
Sohn EH, Patel PJ, MacLaren RE, Adatia FA, Pal B, Webster AR, Tufail A (2011) Responsiveness of choroidal neovascular membranes in patients with R345W mutation in fibulin 3 (Doyne honeycomb retinal dystrophy) to anti-vascular endothelial growth factor therapy. Arch Ophthalmol 129:1626–1628. https://doi.org/10.1001/archophthalmol.2011.338
Stone EM, Lotery AJ, Munier FL, Heon E, Piguet B, Guymer RH, Vandenburgh K, Cousin P, Nishimura D, Swiderski RE, Silvestri G, Mackey DA, Hageman GS, Bird AC, Sheffield VC, Schorderet DF (1999) A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet 22:199–202. https://doi.org/10.1038/9722
Takeuchi T, Hayashi T, Bedell M, Zhang K, Yamada H, Tsuneoka H (2010) A novel haplotype with the R345W mutation in the EFEMP1 gene associated with autosomal dominant drusen in a Japanese family. Invest Ophthalmol Vis Sci 51:1643–1650. https://doi.org/10.1167/iovs.09-4497
McCulloch DL, Marmor MF, Brigell MG, Hamilton R, Holder GE, Tzekov R, Bach M (2015) ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130:1–12. https://doi.org/10.1007/s10633-014-9473-7
Ninomiya W, Mizobuchi K, Hayashi T, Okude S, Katagiri S, Kubo A, Masuhara N, Nakano T (2020) Electroretinographic abnormalities associated with pregabalin: a case report. Doc Ophthalmol 140:279–287. https://doi.org/10.1007/s10633-019-09743-1
Hayashi T, Mizobuchi K, Kameya S, Yoshitake K, Iwata T, Nakano T (2021) A new PDE6A missense variant p.Arg544Gln in rod-cone dystrophy. Doc Ophthalmol 143:107–114. https://doi.org/10.1007/s10633-021-09826-y
Hayashi T, Mizobuchi K, Kikuchi S, Nakano T (2021) Novel biallelic TRPM1 variants in an elderly patient with complete congenital stationary night blindness. Doc Ophthalmol 142:265–273. https://doi.org/10.1007/s10633-020-09798-5
Hayashi T, Murakami Y, Mizobuchi K, Koyanagi Y, Sonoda KH, Nakano T (2021) Complete congenital stationary night blindness associated with a novel NYX variant (p.Asn216Lys) in middle-aged and older adult patients. Ophthalmic Genet 42:412–419. https://doi.org/10.1080/13816810.2021.1904422
Sutter EE, Tran D (1992) The field topography of ERG components in man–I. Photopic Luminance Response Vis Res 32:433–446. https://doi.org/10.1016/0042-6989(92)90235-b
Mizobuchi K, Hayashi T, Oishi N, Kubota D, Kameya S, Higasa K, Futami T, Kondo H, Hosono K, Kurata K, Hotta Y, Yoshitake K, Iwata T, Matsuura T, Nakano T (2021) Genotype-phenotype correlations in RP1-associated retinal dystrophies: a multi-center cohort study in Japan. J Clin Med. https://doi.org/10.3390/jcm10112265
Hoffmann MB, Bach M, Kondo M, Li S, Walker S, Holopigian K, Viswanathan S, Robson AG (2021) ISCEV standard for clinical multifocal electroretinography (mfERG) (2021 update). Doc Ophthalmol 142:5–16. https://doi.org/10.1007/s10633-020-09812-w
Tadaka S, Hishinuma E, Komaki S, Motoike IN, Kawashima J, Saigusa D, Inoue J, Takayama J, Okamura Y, Aoki Y, Shirota M, Otsuki A, Katsuoka F, Shimizu A, Tamiya G, Koshiba S, Sasaki M, Yamamoto M, Kinoshita K (2021) jMorp updates in 2020: large enhancement of multi-omics data resources on the general Japanese population. Nucl Acids Res 49:D536–D544. https://doi.org/10.1093/nar/gkaa1034
Zech JC, Zaouche S, Mourier F, Placuchu H, Grange JD, Trepsat C (1999) Macular dystrophy of malattia leventinese. A 25 year follow up. Br J Ophthalmol 83:1195–1196. https://doi.org/10.1136/bjo.83.10.1194b
Pager CK, Sarin LK, Federman JL, Eagle R, Hageman G, Rosenow J, Donoso LA (2001) Malattia leventinese presenting with subretinal neovascular membrane and hemorrhage. Am J Ophthalmol 131:517–518. https://doi.org/10.1016/s0002-9394(00)00821-7
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, Group AS (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655
Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908. https://doi.org/10.1056/NEJMoa1102673
IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411. https://doi.org/10.1016/j.ophtha.2012.04.015
Berg K, Pedersen TR, Sandvik L, Bragadottir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152. https://doi.org/10.1016/j.ophtha.2014.07.041
Augsburger M, Sarra GM, Imesch P (2019) Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol 257:1889–1895. https://doi.org/10.1007/s00417-019-04404-0
Souied EH, Leveziel N, Querques G, Darmon J, Coscas G, Soubrane G (2006) Indocyanine green angiography features of Malattia leventinese. Br J Ophthalmol 90:296–300. https://doi.org/10.1136/bjo.2005.081802
Evans K, Gregory CY, Wijesuriya SD, Kermani S, Jay MR, Plant C, Bird AC (1997) Assessment of the phenotypic range seen in Doyne honeycomb retinal dystrophy. Arch Ophthalmol 115:904–910. https://doi.org/10.1001/archopht.1997.01100160074012
Zhang T, Xie X, Cao G, Jiang H, Wu S, Su Z, Zhang K, Lu F (2014) Malattia leventinese/Doyne honeycomb retinal dystrophy in a chinese family with mutation of the EFEMP1 gene. Retina 34:2462–2471. https://doi.org/10.1097/IAE.0000000000000259
Acknowledgements
We would like to thank Ritsuko Nakayama for assistance with genetic analysis and Takashi Sato for acquisition of retinal images.
Funding
This work was supported in part by JSPS KAKENHI Grant Number 21K09756 to T.H.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest in this work.
Statement of human rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Statement on the welfare of animals
This article does not contain any studies with animals performed by any of the authors.
Consent to participate
The patient and her parents provided informed consent for participation in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Enomoto, N., Hayashi, T., Matsuura, T. et al. The second Japanese family with Malattia Leventinese/Doyne honeycomb retinal dystrophy. Doc Ophthalmol 144, 67–75 (2022). https://doi.org/10.1007/s10633-021-09859-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10633-021-09859-3